Challenges in optimizing EU market access for immuno-oncology therapies

Challenges in optimizing EU market access for immuno-oncology therapies

Eva Marchese, Cécile Matthews
Life Sciences Strategy

Immuno-oncology therapies are close to delivering on their promise, but still face significant obstacles in terms of expansion to other indications, pricing challenges, and regulatory strategy. Eva Marchese and Cécile Matthews discuss these challenges in their article in The Pharma Letter.

Click here to read the article or download a copy. 

Download PDF